Introduction
Ethnic and racial disparities have been described in the outcome of several cancers and have been attributed to a combination of biologic and nonbiologic factors. [1] [2] [3] [4] Such data in adult acute myeloid leukemia (AML) are largely limited to the comparison of black and white patients. [5] [6] [7] Hispanics are known to have higher rates of B-cell acute lymphoblastic leukemia and acute promyelocytic leukemia (APL), but there exist no definitive data on epidemiologic or outcome differences in non-APL AML compared with whites. [8] [9] [10] We compare the baseline characteristics and treatment outcomes of Hispanic and white AML patients. Such ethnic differences should trigger study of their potentially biologic basis that would contribute to the everlasting struggle to eliminate disease outcome disparities in minorities.
Methods Cohorts
An adult AML cohort was generated from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry. 11, 12 Only AML cases at $18 years of age registered between 2000 and 2010 were examined. APL cases were excluded (ICD-0-3 code 9866/3). We narrowed our search to Hispanics and non-Hispanic whites. We extracted data on demographics, year of diagnosis, duration of follow-up, and vital status.
Cytogenetic information available in the SEER registry was primarily informative for the t(8;21)(q22;q22) RUNX1-RUNX1T1, inv(16)(p13.1q22), and t(16;16)(p13.1;q22)CBFB-MYH11 alterations and did not allow complete cytogenetic risk classification. Two prognostic groups were developed: a favorable group (for the core binding factor leukemias) and a nonfavorable group (for all other cases).
A validation cohort was generated from a minority-rich population of AML patients treated within the Montefiore Medical system in the Bronx, NY, from 1 January 2000 to 31 December 2010, with the use of Clinical Looking Glass, a software tool developed at Montefiore Medical Center. It included all Hispanic and white newly diagnosed AML patients aged $18 years. Demographic information was obtained at patient registration. Ethnicity and race were self-reported.
Manual chart review retrieved data on date of diagnosis, cytogenetics, prior chemotherapy/radiation or myeloid neoplasm, treatment (including allogeneic transplantation), response, and date of death or last known encounter. Three cytogenetic risk categories were generated. [13] [14] [15] [16] All cases of APL were excluded.
We performed targeted sequencing at 5003 coverage (Genoptix, Carlsbad, CA) for genomic profiling of AML cases in Bronx, NY, from 30 November 2013 to 30 October 2016. In conjunction with data from The Cancer Genome Atlas (TCGA) Network, 17 we looked for genomic differences by ethnicity. The study was approved by the Montefiore-Einstein institutional review board in accordance with the Declaration of Helsinki.
Statistical analysis
Age distribution between Hispanic and white AML patients was compared with the Mann-Whitney U test. Comparison of proportions was done with the Pearson's x 2 test or Fisher's exact test for scarce data.
Differences in survival between Hispanics and whites were assessed with the Kaplan-Meier function and tested with the log-rank test. Multivariable Cox proportional hazard models were constructed to look at the mortality risk associated with ethnicity, adjusted for age, sex, cytogenetic risk (in both cohorts) and initial therapy (in the Bronx cohort). Variables selected on the basis of their clinical significance were forced to the models. The linearity assumption was evaluated with fractional polynomial regression, postestimation partial residual plots, and the dummy variable method. The proportional hazard assumption was tested by analysis of Schoenfeld residuals and assessed graphically with log-log curves. Statistical significance was determined at the 2-tailed a .05 level.
Statistical analyses were performed with STATA software, version 12.0.
Results and discussion
The SEER cohort consisted of 2664 Hispanic and 20 905 white AML patients (Table 1 ). The median follow-up time was 8 months.
Hispanics were diagnosed at a significantly younger age than whites (median age 59 vs 71 years; P , .001) and had a slightly higher representation of favorable risk cytogenetics (3.9 vs 2.6%; P , .001) ( Mutational analysis in a Bronx subcohort revealed no statistically significant differences in the frequency of ASXL1 (19.6 vs 12.0%; P 5 .52) and TET2 mutations (23.9 vs 20.0%; P 5 .71) in Hispanics and whites, possibly due to small numbers. However, analysis of a combined cohort with additional AML cases genotyped by the TCGA demonstrated significantly higher frequency of ASXL1 (P , .001) and TET2 mutations (P 5 .03) in Hispanics than in whites (Table 2) .
Differences in treatment intensity are difficult to ascertain outside a randomized clinical trial. In the validation cohort, we found similar rates of intensive chemotherapy, per standard of care protocols, and allogeneic transplantation in both Hispanics and whites. Superior clinical fitness in the younger Hispanic group, donor availability in multimember Hispanic families, and use of haploidentical donors could have counterbalanced minority underrepresentation in donor registries. We had no information on socioeconomic status (SES); however, in the urban population represented by our single-institution cohort, no substantial variations in SES are expected. The concordant results in both cohorts further argue against the confounding effect of treatment or SES. Although a cohort and not a population-based study to allow age-specific AML incidence estimation, the size of the SEER-generated cohort study 
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provides large-scale evidence of differences in age of AML presentation and outcomes between Hispanics and whites. These observations were confirmed in our ethnically diverse validation cohort.
In contrast to Swords et al and in concordance with Patel et al, we observed that Hispanics present with AML at a younger age compared with whites. 8, 10 In addition, age-adjusted OS was surprisingly worse in Hispanics, a result particularly intriguing when seen in context with the so-called Hispanic epidemiologic paradox. 18 Finally, in our study, we attempted for the first time to compare the genomic profile of myeloid neoplasms between the 2 ethnic groups. Differences in representation of Hispanics and de novo cases in the TCGA and Bronx cohorts could confound the comparison and future studies are required for further verification. However, the combined cohort provided a sizeable pool of genomic data, and the results suggest the presence of mutations of adverse prognostic significance at higher frequency in Hispanic than white AML patients, which may provide a biologic explanation for the inferior outcomes of the former.
The underlying cause of the observed ethnic differences in age of onset and biologic behavior of AML remains elusive. Future investigation into how the complex interaction between environmental exposures and genetic factors impacts AML development may one day help to further elucidate our observations. These data support ethnicity-specific analysis of germline and somatic mutations in future studies. Conflict-of-interest disclosure: The authors declare no competing financial interests. Data are presented as n (%) of patients unless otherwise indicated.
